• breast cancer - HER2-positive
• es-BC - HER2 negative - (neo)adjuvant (NA) 1
• es-BC - HER2 positive - (neo)adjuvant (NA) 4
• la/mBC - HER2 positive
• la/mBC - HER2 positive - (neo)adjuvant (NA)
• la/mBC - HER2 positive - 1st Line (L1) 5
• la/mBC - HER2 positive - 2nd Line (L2) 13

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs taxanes
• vs paclitaxel
• vs paclitaxel followed by doxorubicin plus cyclophosphamide

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)